Findings

The Congress finds the following:(1)Pharmacy benefit managers are corporate entities that play a dominant role in pharmaceutical supply chains, determining which drugs health plans will cover for enrollees, what prices patients and health plans will pay for those drugs, and how much health plans will reimburse pharmacies for dispensing them.(2)The market for pharmacy benefit manager services has become highly concentrated. As of 2025, the 6 largest pharmacy benefit managers are each integrated into large health care conglomerates that include downstream businesses such as retail, mail order, and specialty pharmacies. These conglomerates also processed more than 90 percent of the prescriptions in the United States in 2023.(3)The 3 largest pharmacy benefit managers are also vertically integrated into health care platforms that include both upstream business lines, like health insurance, and downstream suppliers, like pharmacies and providers.(4)The Federal Trade Commission has found that vertically integrated pharmacy benefit managers have both the ability and incentive to steer business to their own affiliated pharmacies, which reduces competition and increases prescription drug costs for patients.(5)Pharmacy benefit managers increasingly leverage their market power to pressure smaller, unaffiliated, independent pharmacies to enter into unfavorable contracts with the largest pharmacy benefit managers. This dynamic has likely contributed to the closure of more than 7,000 pharmacies between 2019 and 2024.(6)Self-preferencing of affiliated pharmacies may also allow large, vertically integrated health conglomerates to evade statutory limits on profits known as the Medical Loss Ratio. Gaming of the profit constraint using transfer pricing techniques may allow affiliated health insurance businesses to hide profits in the unregulated pharmacy business segment, costing enrollees and taxpayers money.(7)Pursuant to its powers under article I, section 8, of the United States Constitution, Congress has the ability to create any law necessary and appropriate to regulate interstate commerce. As pharmacy benefit managers are part of large, national health conglomerates that operate across state lines, and engage in intrastate activities that also substantially relate to interstate commerce, Congress intends to regulate pharmacy benefit managers in the public interest.(8)In order to eliminate the conflicts of interest described in paragraphs (1) through (7) and restore competition to the marketplace, the Federal Government should—(A)protect patients, independent pharmacies, and taxpayers by structurally separating vertically integrated health conglomerates;(B)require parent companies that own a pharmacy benefit manager or insurer to divest their pharmacy businesses;(C)enable Federal agencies, state attorneys general, and private citizens to bring civil actions to enforce the structural separation of these companies; and(D)grant the Federal Trade Commission and Department of Justice additional authority to review and block future transactions that would re-create these conflicts of interest.

Prohibitions relating to anticompetitive pharmacy ownership and contracts

(a)

Prohibition on pharmacy ownership by entities providing insurance or pharmacy benefit management services

(1)

In general

It shall be unlawful for any person to both—(A)directly or indirectly own, operate, control, or direct the operation of the whole or any part of a pharmacy; and(B)directly or indirectly own, operate, or control the whole or any part of—(i)an insurance company; or(ii)a pharmacy benefit manager.(2)

Divestment

Not later than 1 year after the date of enactment of this Act, any person in violation of paragraph (1) shall divest the pharmacy of such person.(b)

Antitrust enforcement

(1)

In general

Both the Federal Trade Commission and the Assistant Attorney General in charge of the Antitrust Division shall have jurisdiction, jointly or separately, to enforce this section.(2)

Penalties for failure to divest

(A)

Guidance

Not later than 30 days after the date of enactment of this Act, the Chair of the Federal Trade Commission and the Assistant Attorney General in charge of the Antitrust Division shall issue guidance specifying milestones for divestment within the deadline under subsection (a)(2).(B)

Penalties

(i)

In general

For any person that does not comply with the milestones specified under subparagraph (A), the Chair of the Federal Trade Commission or the Assistant Attorney General in charge of the Antitrust Division shall cause 10 percent of the profits of the person to be transferred into escrow on a monthly basis, to be—(I)returned to the person if divestment occurs by the deadline under subsection (a)(2); or(II)deposited into the fund described in subsection (c)(7) if divestment does not occur by the deadline under subsection (a)(2).(C)

Trustee

If divestiture does not occur by the deadline under subsection (a)(2), a divestiture trustee shall oversee the divestiture required under that paragraph. The divestiture trustee shall have the authority to sell the pharmacy.(c)

Civil actions

(1)

In general

When the Inspector General of the Department of Health and Human Services, the Assistant Attorney General in charge of the Antitrust Division of the Department of Justice, the Federal Trade Commission, or an attorney general of a State has reason to believe that a person is in violation of subsection (a), such Inspector General, Assistant Attorney General, Federal Trade Commission or attorney general of a State may bring a civil action in an appropriate district court of the United States.(2)

Private right of action

(A)

In general

An individual alleging damages as a result of a violation of this Act may bring a civil action in any court of competent jurisdiction, State or Federal.(B)

Relief

In a civil action brought under subparagraph (A) in which the plaintiff prevails, the court may award—(i)treble damages;(ii)reasonable attorney’s fees and litigation costs; and(iii)any other relief, including equitable or declaratory relief, that the court determines appropriate.(3)

Actions by State attorneys general

If the attorney general of a State has reason to believe that an interest of the residents of the State has been or is being threatened or adversely affected by a practice that violates subsection (a), the attorney general of the State may, as parens patriae, bring a civil action on behalf of the residents of the State in an appropriate district court of the United States to obtain appropriate relief, including monetary damages.(4)

Injunctive and equitable relief

In any action described in paragraph (1), (2), or (3), the applicable court, on a finding that a person is in violation of subsection (a), shall issue an order requiring such person—(A)to cease and desist from such violation, and, if applicable, divest the pharmacy services of such person; and(B)to disgorge any revenue received from the pharmacy from the sale of prescription drugs during the period of such violation.(5)

Other relief

In addition to any relief obtained under paragraph (1), (2), or (3), the court may grant any other equitable relief necessary to redress and prevent recurrence of the violation.(6)

Right to jury trial

Either party, upon request, shall have the right to a jury trial.(7)

Deposit

Any revenue received from the sale of prescription drugs disgorged pursuant to an action under paragraph (1) shall be deposited in a fund created by the Federal Trade Commission and distributed by the Federal Trade Commission to be put to use in the interest of serving the health care needs of the harmed community, including consumers overcharged at vertically integrated pharmacies.(d)

FTC and DOJ review

(1)

Reporting required

Any divestment of a pharmacy or pharmacy benefit manager required under subsection (a) shall be reported to the Federal Trade Commission and the Assistant Attorney General in charge of the Antitrust Division of the Department of Justice under section 7A of the Clayton Act (15 U.S.C. 18a) without respect to the thresholds under subsection (a)(2) of that section.(2)

Tolling of divestment period during review

The divestment period under subsection (a) shall be tolled during the pendency of any waiting period required under section 7A of the Clayton Act (15 U.S.C. 18a).(3)

Review of effect of divestiture

With respect to each divestiture undertaken pursuant to subsection (a), in addition to any applicable review under section 7A of the Clayton Act (15 U.S.C. 18a), the Federal Trade Commission and the Assistant Attorney General in charge of the Antitrust Division of the Department of Justice shall review the effect on competition, financial viability, and the public interest—(A)of the divestiture; and(B)of the subsequent acquisition of the divested pharmacy by the acquiring person.(4)

Blocking of actions

The Federal Trade Commission and the Assistant Attorney General in charge of the Antitrust Division of the Department of Justice, jointly or separately, may bring a civil action in any court of competent jurisdiction to block any action that would harm competition to the detriment of the public interest with respect to the conflicts of interest described in subsection (a).(e)

Rulemaking authority

The Federal Trade Commission shall promulgate rules to carry out this section. Such rules shall not diminish any obligation under this section.(f)

Reports required

The Chair of the Federal Trade Commission and the Assistant Attorney General in charge of the Antitrust Division of the Department of Justice shall submit to the appropriate congressional committees quarterly reports on compliance with this Act, including the status of any divestitures required under this Act.(g)

Rule of construction

Nothing in this section shall be construed to limit the authority of the Federal Trade Commission, the Inspector General of the Department of Justice, the Department of Health and Human Services, or the attorney general of a State under any other provision of law.(h)

Severability

If any provision of this Act or the application thereof to any person or circumstance is held invalid, the remainder of this Act, or the application of that provision to persons or circumstances other than those as to which it is held invalid, shall not be affected thereby.(i)

Definitions

In this section:(1)

Health plan

The term health plan means any public or private health insurance plan.(2)

Person

The term person has the meaning given the term in section 8 of the Sherman Act (15 U.S.C. 7).(3)

Pharmacy

(A)

In general

The term pharmacy means any person, business, or entity licensed, registered, or otherwise permitted by a State or a territory of the United States to dispense, deliver, or distribute a controlled substance, prescription drug, or other medication—(i)to the general public; or(ii)to a bed patient for immediate administration.(B)

Inclusions

The term pharmacy includes—(i)a mail-order pharmacy;(ii)a specialty pharmacy;(iii)a retail pharmacy;(iv)a nursing home pharmacy;(v)a long-term care pharmacy;(vi)a hospital pharmacy;(vii)an infusion or other outpatient treatment pharmacy;(viii)any organization the National Provider Identifier (NPI) registration of which has 1 or more taxonomy codes under the pharmacy section of the National Uniform Claim Committee (or a subsequent organization); and(ix)any other type of pharmacy.(4)

Pharmacy benefit manager

The term pharmacy benefit manager means any person, business, or other entity, such as a third-party administrator, regardless of whether such person, business, or entity identifies itself as a pharmacy benefit manager, that, either directly or indirectly through an intermediary (including an affiliate, subsidiary, or agent) or an arrangement with a third party—(A)acts as a negotiator of prices, rebates, fees, or discounts for prescription drugs on behalf of a health plan or health plan sponsor;(B)contracts with pharmacies to create pharmacy networks and designs and manages such networks; or(C)manages or administers the prescription drug benefits provided by a health plan, including the processing and payment of claims for prescription drugs, arranging alternative access to or funding for prescription drugs, the performance of utilization management services, including drug utilization review, the processing of drug prior authorization requests, the adjudication of appeals or grievances related to the prescription drug benefit, contracting with network pharmacies, controlling the cost of covered prescription drugs, or the provision of related services.